Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTHY57M)

• DTT Name: Matrix metalloproteinase-13 (MMP-13) DTT Info
• Gene Name: MMP13

Molecule-Related Drug & Molecule List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
Apratastat	DM8W4N9	Rheumatoid arthritis	FA20	Phase 2	[2]
PMID17935984C1	DMO1IHL	Pain	MG30-MG3Z	Clinical trial	[3]

5 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29130358-Compound-Figure16(9a)	DMKX5R8	N. A.	N. A.	Patented	[4]
PMID29130358-Compound-Figure16(9b)	DMPAQLZ	N. A.	N. A.	Patented	[4]
PMID29130358-Compound-Figure16(9c)	DM0ZRI9	N. A.	N. A.	Patented	[4]
PMID29130358-Compound-Figure18(14)	DM7WXJ9	N. A.	N. A.	Patented	[4]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[4]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[5]
RS-130830	DMOTANY	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[6]

40 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	DMSN7GJ	Discovery agent	N.A.	Investigative	[7]
1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol	DMZWRU7	Discovery agent	N.A.	Investigative	[8]
1-Methyloxy-4-Sulfone-Benzene	DMFR7JW	Discovery agent	N.A.	Investigative	[9]
2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	DM95B4J	Discovery agent	N.A.	Investigative	[7]
2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol	DMZNPMQ	Discovery agent	N.A.	Investigative	[10]
2-(biphenyl-4-ylsulfonamido)pentanedioic acid	DMH3YBR	Discovery agent	N.A.	Investigative	[10]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	DMCNV5J	Discovery agent	N.A.	Investigative	[11]
3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	DM206M1	Discovery agent	N.A.	Investigative	[12]
3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	DMK79U1	Discovery agent	N.A.	Investigative	[12]
3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	DMRLAX8	Discovery agent	N.A.	Investigative	[8]
3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	DM854IG	Discovery agent	N.A.	Investigative	[8]
3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	DM7B1VT	Discovery agent	N.A.	Investigative	[8]
3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	DMBKDZ3	Discovery agent	N.A.	Investigative	[12]
3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	DM2HBGL	Discovery agent	N.A.	Investigative	[8]
3-Benzenesulfonyl-heptanoic acid hydroxyamide	DM7XDCF	Discovery agent	N.A.	Investigative	[13]
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	DMJSOTE	Discovery agent	N.A.	Investigative	[13]
3-Methylpyridine	DMF3JHM	Discovery agent	N.A.	Investigative	[9]
4-(2,2'-bithiophen-5-ylmethyleneamino)phenol	DMRZY0B	Discovery agent	N.A.	Investigative	[1]
4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	DM5PTB9	Discovery agent	N.A.	Investigative	[8]
4-(methyl(4-phenylthiazol-2-yl)amino)phenol	DMQCMFU	Discovery agent	N.A.	Investigative	[1]
4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	DMGI0YV	Discovery agent	N.A.	Investigative	[10]
5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	DMTDNX3	Discovery agent	N.A.	Investigative	[7]
CL82198	DMP3MDS	Discovery agent	N.A.	Investigative	[14]
Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate	DM06AQZ	Discovery agent	N.A.	Investigative	[1]
Hydroxyaminovaline	DMUVCRQ	Discovery agent	N.A.	Investigative	[9]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[15]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[16]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	DM4VADN	Discovery agent	N.A.	Investigative	[11]
N1,N3-bis(3-methoxybenzyl)isophthalamide	DMA5Z7P	Discovery agent	N.A.	Investigative	[17]
N4,N6-dibenzylpyrimidine-4,6-dicarboxamide	DMCR13E	Discovery agent	N.A.	Investigative	[18]
PD-156	DMY5SX9	Inflammation	1A00-CA43.1	Investigative	[19]
PKF-242-484	DMNDLAS	Discovery agent	N.A.	Investigative	[20]
PMID22017539C15	DMWBYNF	Discovery agent	N.A.	Investigative	[21]
Ro-37-9790	DM83QMZ	Discovery agent	N.A.	Investigative	[22]
SL422	DM3I2US	Discovery agent	N.A.	Investigative	[23]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[24]
UK-356618	DM02FGH	Discovery agent	N.A.	Investigative	[25]
WAY-151693	DMRWG0C	Discovery agent	N.A.	Investigative	[9]
WAY170523	DMZT8LI	Discovery agent	N.A.	Investigative	[14]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	DM37C25	Discovery agent	N.A.	Investigative	[11]

References

• [1] High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
• [2] Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
• [3] Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
• [4] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [5] Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
• [6] Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
• [7] The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
• [8] Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
• [11] Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
• [12] Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
• [13] Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637).
• [15] Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
• [16] Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
• [17] Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment ... Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80.
• [18] Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13. Bioorg Med Chem Lett. 2009 Jan 1;19(1):47-50.
• [19] Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
• [20] A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
• [21] Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87.
• [22] 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
• [23] Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
• [24] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
• [25] A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.